Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease

Clinical Gastroenterology and Hepatology

Volumn 15, Issue 1, 2017, Pages 25-36.e27

  Peyrin Biroulet, Laurent ^a   Van Assche, Gert ^b   Gómez Ulloa, David ^c   García Álvarez, Laura ^c   Lara, Núria ^c   Black, Chris M ^d   Kachroo, Sumesh ^d  

^a UNIVERSITÉ DE LORRAINE   (France)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c IQVIA   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Extraintestinal Manifestations; Inflammatory Bowel Disease; Systematic Review

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; BIOLOGICAL PRODUCT; IMMUNOLOGIC FACTOR; TUMOR NECROSIS FACTOR;

ANEMIA; ANKYLOSING SPONDYLITIS; ARTHRALGIA; ARTHRITIS; ARTHROPATHY; BACKACHE; CROHN DISEASE; DISEASES; DRUG EFFICACY; ENTHESITIS; EPISCLERITIS; ERYTHEMA NODOSUM; EXTRAINTESTINAL MANIFESTATION; HUMAN; INFLAMMATORY BOWEL DISEASE; IRITIS; META ANALYSIS; METABOLIC BONE DISEASE; MULTICENTER STUDY (TOPIC); MUSCULOSKELETAL DISEASE; OSTEOPENIA; OSTEOPOROSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PYODERMA GANGRENOSUM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SACROILIITIS; SKIN DISEASE; STOMATITIS; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; UVEITIS; ANTAGONISTS AND INHIBITORS; INFLAMMATORY BOWEL DISEASES; TREATMENT OUTCOME;

BIOLOGICAL PRODUCTS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84994893494     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.06.025     Document Type: Review

References (49)

1. 1 Zippi, M., Corrado, C., Pica, R., et al. Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients. World J Gastroenterol 20 (2014), 17463–17467.
2. 2 Vavricka, S.R., Brun, L., Ballabeni, P., et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 106 (2011), 110–119.
3. 3 Isene, R., Bernklev, T., Høie, O., et al. Extraintestinal manifestations in Crohn's disease and ulcerative colitis: results from a prospective, population-based European inception cohort. Scand J Gastroenterol 50 (2015), 300–305.
4. 4 Ott, C., Takses, A., Obermeier, F., et al. Smoking increases the risk of extraintestinal manifestations in Crohn's disease. World J Gastroenterol 20 (2014), 12269–12276.
5. 5 Robinson, R.J., al-Azzawi, F., Iqbal, S.J., et al. Osteoporosis and determinants of bone density in patients with Crohn's disease. Dig Dis Sci 43 (1998), 2500–2506.
6. 6 Koutroubakis, I.E., Zavos, C., Damilakis, J., et al. Low bone mineral density in Greek patients with inflammatory bowel disease: prevalence and risk factors. Ann Gastroenterol 24 (2011), 41–46.
7. 7 Frei, P., Fried, M., Hungerbuhler, V., et al. Analysis of risk factors for low bone mineral density in inflammatory bowel disease. Digestion 73 (2006), 40–46.
8. 8 Schoon, E.J., van Nunen, A.B., Wouters, R.S., et al. Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort. Scand J Gastroenterol Suppl 232 (2000), 43–47.
9. 9 Pellicer, Z., Santiago, J.M., Rodriguez, A., et al. Management of cutaneous disorders related to inflammatory bowel disease. Ann Gastroenterol 25 (2012), 21–26.
10. 10 Ji, X.Q., Wang, L.X., Lu, D.G., Pulmonary manifestations of inflammatory bowel disease. World J Gastroenterol 20 (2014), 13501–13511.
11. 11 Peluso, R., Manguso, F., Vitiello, M., et al. Management of arthropathy in inflammatory bowel diseases. Ther Adv Chronic Dis 6 (2015), 65–77.
12. 12 Barreiro-de Acosta, M., Iglesias-Rey, M., Lorenzo, A., et al. P639 influence of extraintestinal manifestations in health-related quality of life in inflammatory bowel disease patients. J Crohns Colitis 7:Suppl 1 (2013), S266–S267.
13. 13 Isene, R., Munkholm, P., Stockbrügger, R., et al. M1126 extraintestinal manifestations of inflammatory bowel disease and their impact on quality of life: results from the European Collaborative Study of Inflammatory Bowel Disease (EC-IBD). Gastroenterology, 136, 2009, A-355.
14. 14 Harbord, M., Annese, V., Vavricka, S.R., et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis 10 (2016), 239–254.
15. 15 Andrisani, G., Guidi, L., Papa, A., et al. Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease. Eur Rev Med Pharmacol Sci 16 (2012), 890–901.
16. 16 Barrie, A., Regueiro, M., Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 13 (2007), 1424–1429.
17. 17 Zippi, M., Pica, R., De Nitto, D., et al. Biological therapy for dermatological manifestations of inflammatory bowel disease. World J Clin Cases 1 (2013), 74–78.
18. 18 Vavricka, S.R., Scharl, M., Gubler, M., et al. Biologics for extraintestinal manifestations of IBD. Curr Drug Targets 15 (2014), 1064–1073.
19. 19 Liberati, A., Altman, D.G., Tetzlaff, J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ, 339, 2009, b2700.
20. 20 Centre for Reviews and Dissemination (CRD). Undertaking systematic reviews of research on effectiveness. CRD Report 4. 2nd ed., 2001, University of York, York, UK.
21. 21 National Heart Lung and Blood Institute. Quality assessment tool for observational cohort and cross-sectional studies. Available at: http://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/cohort. Accessed June 1, 2016.
22. 22 Brooklyn, T.N., Dunnill, M.G., Shetty, A., et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55 (2006), 505–509.
23. 23 Kaufman, I., Caspi, D., Yeshurun, D., et al. The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int 25 (2005), 406–410.
24. 24 Rubin, D.T., Mulani, P., Chao, J., et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflamm Bowel Dis 18 (2012), 818–825.
25. 25 Colombel, J.F., Sandborn, W.J., Rutgeerts, P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132 (2007), 52–65.
26. 26 Rispo, A., Scarpa, R., Di Girolamo, E., et al. Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease. Scand J Rheumatol 34 (2005), 387–391.
27. 27 Herfarth, H., Obermeier, F., Andus, T., et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. Am J Gastroenterol 97 (2002), 2688–2690.
28. 28 Generini, S., Giacomelli, R., Fedi, R., et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 63 (2004), 1664–1669.
29. 29 Löfberg, R., Louis, E.V., Reinisch, W., et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE. Inflamm Bowel Dis 18 (2012), 1–9.
30. 30 Barreiro-de-Acosta, M., Lorenzo, A., Domínguez-Muñoz, J.E., Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease. Rev Esp Enferm Dig 104 (2012), 468–472.
31. 31 Veerappan, S.G., Healy, M., Walsh, B.J., et al. Adalimumab therapy has a beneficial effect on bone metabolism in patients with Crohn's disease. Dig Dis Sci 60 (2015), 2119–2129.
32. 32 Bernstein, M., Irwin, S., Greenberg, G.R., Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am J Gastroenterol 100 (2005), 2031–2035.
33. 33 Mauro, M., Radovic, V., Armstrong, D., Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients. Can J Gastroenterol 21 (2007), 637–642.
34. 34 Pazianas, M., Rhim, A.D., Weinberg, A.M., et al. The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease. Ann N Y Acad Sci 1068 (2006), 543–556.
35. 35 Abreu, M.T., Geller, J.L., Vasiliauskas, E.A., et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J Clin Gastroenterol 40 (2006), 55–63.
36. 36 Franchimont, N., Putzeys, V., Collette, J., et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther 20 (2004), 607–614.
37. 37 Ryan, B.M., Russel, M.G., Schurgers, L., et al. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study. Aliment Pharmacol Ther 20 (2004), 851–857.
38. 38 Koutroubakis, I.E., Ramos-Rivers, C., Regueiro, M., et al. The influence of anti-tumor necrosis factor agents on hemoglobin levels of patients with inflammatory bowel disease. Inflamm Bowel Dis 21 (2015), 1587–1593.
39. 39 Bergamaschi, G., Di Sabatino, A., Albertini, R., et al. Prevalence and pathogenesis of anaemia in inflammatory bowel disease: influence of anti-tumor necrosis factor-alpha treatment. Haematologica 95 (2010), 199–205.
40. 40 Argüelles-Arias, F., Castro-Laria, L., Lobatón, T., et al. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. Dig Dis Sci 58 (2013), 2949–2954.
41. 41 Regueiro, M., Valentine, J., Plevy, S., et al. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 98 (2003), 1821–1826.
42. 42 Wang, X., Wang, G., Wang, J., et al. Coagulation state in patients with Crohn's disease: the effect of infliximab therapy. Eur J Gastroenterol Hepatol 26 (2014), 955–963.
43. 43 Bollen, L., Vande Casteele, N., Peeters, M., et al. Short-term effect of infliximab is reflected in the clot lysis profile of patients with inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 21 (2015), 570–578.
44. 44 Caspersen, S., Elkjaer, M., Riis, L., et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 6 (2008), 1212–1217.
45. 45 Rubin, D., Feagan, B., Dryden, G., et al. The effect of vedolizumab on extraintestinal manifestations in patients with Crohn's disease in GEMINI 2. Inflamm Bowel Dis, 22, 2016.
46. 46 Hirten, R., Longman, R.S., Bosworth, B.P., et al. Vedolizumab and infliximab combination therapy in the treatment of Crohn's disease. Am J Gastroenterol 110 (2015), 1737–1738.
47. 47 Morrison, A., Polisena, J., Husereau, D., et al. The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care 28 (2012), 138–144.
48. 48 Berkman, N.D., Lohr, K.N., Ansari, M., et al. Grading the strength of a body of evidence when assessing health care interventions for the effective health care program of the Agency for Healthcare Research and Quality: an update—methods guide for comparative effectiveness reviews. AHRQ publication no. 13(14)-EHC130-EF. 2013, Agency for Healthcare Research and Quality, Rockville, MD Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm.
49. 49 Balshem, H., Stevens, A., Ansari, M., et al. Finding grey literature evidence and assessing for outcome and analysis reporting biases when comparing medical interventions: AHRQ and the effective health care program—methods guide for comparative effectiveness reviews. AHRQ publication no. 13(14)-EHC096-EF. 2013, Agency for Healthcare Research and Quality, Rockville, MD Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm.